IP Library › Granted Patent US 7,524,965
Granted Patent B2
US 7,524,965 · App. 11/789,300 · Granted Apr 28, 2009

Dialkylphenyl compounds having β

Assignee: Theravance, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,524,965
App. No.
11/789,300
Granted
Apr 28, 2009
Kind
B2
Abstract

This invention relates to compounds of formula I: wherein R 1 and R 2 are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The invention also relates to pharmaceutical compositions and combinations comprising such compounds, processes and intermediates for preparing such compounds, and methods of using such compound to, for example, treat pulmonary disorders, such as chronic obstructive pulmonary disease and asthma.

Claims (25)

1. A compound of formula I:

wherein

R 1 is methyl or ethyl;

R 2 is methyl or ethyl;

or a pharmaceutically acceptable salt or stereoisomer thereof.

2. A compound of formula II:

wherein

R 1 is methyl or ethyl;

R 2 is methyl or ethyl;

or a pharmaceutically acceptable salt thereof.

3. A compound of formula IIa:

4. A pharmaceutically acceptable salt of a compound of formula IIa:

5. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the compound of any one of claims 1 to 4 .

6. A process of preparing the compound of claim 1 , the process comprising deprotecting a compound of formula 6:

wherein P 1 is a hydroxyl-protecting group, to provide a compound of formula I.

7. A process of preparing the compound of claim 1 , the process comprising deprotecting a compound of formula 6a:

wherein R a , R b and R c are independently selected from C 1-4 alkyl, phenyl, —C 1-4 alkyl-(phenyl), or one of R 1a , R 1b and R 1c is —O—(C 1-4 alkyl); to provide a compound of formula I.

8. A process of preparing the compound of claim 1 , the process comprising:

(a) reacting a compound of formula 4:

with a compound of formula 5:

wherein P 1 is a hydroxyl-protecting group, in the presence of a reducing agent to provide a compound of formula 6:

and

(b) deprotecting the compound of formula 6 to provide a compound of formula I.

9. A process of preparing a pharmaceutically acceptable salt of the compound of claim 1 , the process comprising contacting a compound of formula I in free base form with a pharmaceutically acceptable acid.

10. Biphenyl-2-ylcarbamic acid 1-[2-(4-{[(R)-2-(3-formylamino-4-hydroxyphenyl)-2-hydroxyethylamino]methyl}-2,5-dimethylphenyl-carbamoyl)ethyl]piperidin-4-yl ester L-tartaric acid salt.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 12, 2020
From: THERAVANCE RESPIRATORY COMPANY, LLC
To: THERAVANCE BIOPHARMA R&D IP, LLC
Reel/Frame 054393/0695 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 10, 2014
From: THERAVANCE, INC.
To: THERAVANCE RESPIRATORY COMPANY, LLC
Reel/Frame 033175/0553 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 9, 2007
From: COLSON, PIERRE-JEAN; HUGHES, ADAM D.; HUSFELD, CRAIG; MAMMEN, MATHAI; RAPTA, MIROSLAV
To: THERAVANCE, INC.
Reel/Frame 019535/0025 →
Continuity (2)
Provisional Application 6079470200 · Apr 25, 2006
Related Publication 20070249675A1 · Oct 25, 2007